Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares MSCI South Korea ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while iShares MSCI South Korea ETF trades at $179.42. Which is the better fit depends on your goals.
| ACAD | EWY | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $28.06 | $219.20 |
52-Week Low | $20.06 | $70.65 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
The iShares MSCI South Korea ETF (EWY) trades at $189.85, up 5.33% over 24 hours, amid volatile South Korean equity markets. Technical indicators show a bearish trend with key support at $185 and resistance at $192. Recent news highlights strong AI-driven semiconductor demand boosting South Korean stocks, but weak EV battery demand and market volatility pose headwinds.
EWY's outlook hinges on AI memory demand and Samsung's performance, with potential gains from SK Hynix's U.S. listing. Risks include semiconductor cycle volatility and foreign investor selling. The ETF remains a high-beta play on South Korea's tech sector, requiring careful risk management amid elevated market swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
